TD Cowen raised the firm’s price target on Iqvia (IQV) to $213 from $174 and keeps a Buy rating on the shares. The firm does not see AI driving revenue headwinds for the company. While AI is likely to reduce drug trial costs by 10%-15%, the savings will be redeployed into additional activity, the analyst tells investors in a research note. TD sees an attractive risk/reward with Iqvia shares down 24% since the start of February.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia upgraded to Overweight from Equal Weight at Barclays
- MongoDB downgraded, Block upgraded: Wall Street’s top analyst calls
- Iqvia initiated with an Outperform at RBC Capital
- Iqvia to acquire certain discovery services assets from Charles River
- Iqvia price target lowered to $215 from $266 at Mizuho